Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of HRS-5346 in healthy subjects
NCT06441227Phase 1Completed
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Jun 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MK-7262 in lipoprotein disorder (3 arms), sponsored by Shandong Suncadia Medicine Co., Ltd. Primary endpoint: Incidence and severity of adverse events at 3 months. Started Jun 2024; status: completed.
02
Drugs
MK-7262
03
Conditions
lipoprotein disorder
Beyond the preview
Go deeper on NCT06441227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06441227.